Obstetrics & Gynecology, Female Pelvic Medicine and Reconstructive Surgery · Albany, NY
NPI
1659332765
Since 2006
Specialty
Obstetrics & Gynecology, Female Pelvic Medicine and Reconstructive Surgery
Code 207VF0040X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
5 Palisades Dr, Suite 220
Albany, NY, 12205
Phone (518) 438-5538
Groups this clinician bills Medicare through
Medicare paid, 2024
$227K
3,884 services
Medicare patients, 2024
503
Average age 75
Drug cost, 2024
$1.3M
4,286 prescriptions
Company payments, 2025
$831
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert W Lobel was code 81002 (clinical chemistry), 886 times for 403 patients. In total Robert W Lobel billed 3,884 services in 66 codes, and Medicare paid $227K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-02-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 81002 Clinical Chemistry | Office | 886 | 403 | $3.40 | $3,014 |
| 99213 Office E&M - Established | Office | 601 | 376 | $58.23 | $35K |
| 99211 Office E&M - Established | Office | 270 | 73 | $15.57 | $4,204 |
| 51701 Other Organ Systems | Office | 241 | 131 | $27.89 | $6,721 |
| 51741 Test - Miscellaneous | Office | 203 | 119 | $7.55 | $1,532 |
| 99459 Office/Outpatient Services | Office | 167 | 126 | $15.29 | $2,553 |
| 95972 Electrical Nerve Conductivity | Office | 142 | 73 | $37.75 | $5,361 |
| 52281 Calculus Removal - Urinary | Office | 138 | 124 | $196.04 | $27K |
| 99214 Office E&M - Established | Office | 125 | 111 | $85.04 | $11K |
| 64566 Musculoskeletal | Office | 121 | 11 | $80.50 | $9,741 |
| 99212 Office E&M - Established | Office | 115 | 91 | $35.23 | $4,052 |
| 99205 Office E&M - New | Office | 96 | 96 | $135.74 | $13K |
| 51729 Other Organ Systems | Office | 61 | 58 | $264.78 | $16K |
| 51784 Neurologic | Office | 58 | 58 | $22.49 | $1,304 |
| 51797 Other Organ Systems | Office | 57 | 57 | $133.51 | $7,610 |
By year: 2022 $196K for 3,834 services; 2023 $206K for 4,018 services; 2024 $227K for 3,884 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81002 Clinical Chemistry | 886 | 403 | $3.40 | $3,014 |
Medicare prescription drug claims, 2024
In 2024, the drug Robert W Lobel prescribed most often to Medicare patients was Myrbetriq (Mirabegron), with 491 prescriptions and refills. In total Robert W Lobel wrote 4,286 Medicare prescriptions that cost $1.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Myrbetriq Mirabegron | 491 | 1,136 | 146 | $539K |
| Gemtesa Vibegron | 382 | 932 | 117 | $437K |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 283 | 291 | 188 | $3,486 |
| Ciprofloxacin Hcl Generic | 262 | 300 | 144 | $1,751 |
| Cephalexin Generic | 247 | 426 | 114 | $3,013 |
| Trimethoprim Generic | 241 | 646 | 78 | $22K |
| Fluconazole Generic | 230 | 236 | 130 | $2,373 |
| Oxybutynin Chloride Er Oxybutynin Chloride | 219 | 517 | 52 | $6,236 |
| Nitrofurantoin Nitrofurantoin Macrocrystal | 201 | 531 | 66 | $12K |
| Estradiol Generic | 182 | 422 | 73 | $16K |
| Levofloxacin Generic | 131 | 131 | 88 | $660 |
| Solifenacin Succinate Generic | 122 | 321 | 32 | $17K |
| Premarin Estrogens, Conjugated | 112 | 262 | 59 | $51K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 86 | 86 | 55 | $300 |
| Trospium Chloride Generic | 84 | 180 | 28 | $6,418 |
Brand drugs: 1,392 claims; generic drugs: 2,877 claims; opioid claims: 16.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Robert W Lobel $831 ($831 in general payments such as food, travel and fees) from 4 companies. The largest payer was Medtronic, Inc. with $596.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.